Central University of Punjab

Sonipat, India

Not to be confused with University of Central Punjab, Pakistan.The Central University of Punjab is a Central University located in Bathinda, Punjab, India. It has been established through an Act of Parliament: “The Central Universities Act, 2009" by Govt. of India. The territorial jurisdiction of Central University of Punjab is whole of the State of Punjab. Central University of Punjab has been ranked as number one amongst newly established central universities in India consistently since 2012 as per university rankings of Researchgate and Scopus.The Central Universities Bill 2009 aims at creating one new central university each in Bihar, Gujarat, Haryana, Himachal Pradesh, Jammu and Kashmir, Jharkhand, Karnataka, Kerala, Orissa, Punjab, Rajasthan and Tamil Nadu. It also seeks to convert Guru Ghasidas Vishwavidyalaya in Chhattisgarh, Harisingh Gour Vishwavidyalaya in Sagar and Hemwati Nandan Bahuguna Garhwal University in Uttarakhand into Central universities. Wikipedia.

Time filter
Source Type

Singh R.P.,National Institute of Pharmaceutical Education and Research | Singh R.P.,Evalueserve SEZ Gurgaon Pvt. Ltd | Ramarao P.,National Institute of Pharmaceutical Education and Research | Ramarao P.,Central University of Punjab
Toxicological Sciences | Year: 2013

Polymeric nanoparticles (PNPs) are a promising platform for drug, gene, and vaccine delivery. Although generally regarded as safe, the toxicity of PNPs is not well documented. The present study investigated in vitro toxicity of poly-ε-caprolactone, poly(DL-lactic acid), poly(lactide-cocaprolactone), and poly(lactide-co-glycide) NPs and possible mechanism of toxicity. The concentration-dependent effect of PNPs on cell viability was determined in a macrophage (RAW 264.7), hepatocyte (Hep G2), lung epithelial (A549), kidney epithelial (A498), and neuronal (Neuro 2A) cell lines. PNPs show toxicity at high concentrations in all cell lines. PNPs were efficiently internalized by RAW 264.7 cells and stimulated reactive oxygen species and tumor necrosis factor-alpha production. However, reactive nitrogen species and interleukin-6 production as well as lysosomal and mitochondrial stability remained unaffected. The intracellular degradation of PNPs was determined by monitoring changes in osmolality of culture medium and a novel fluorescence recovery after quenching assay. Cell death showed a good correlation with osmolality of culture medium suggesting the role of increased osmolality in cell death. © The Author 2013. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved.

Insan M.B.,Central University of Punjab | Jaitak V.,Central University of Punjab
Mini-Reviews in Medicinal Chemistry | Year: 2014

Resistance towards chemotherapy and radiotherapy as well as relapse of cancer is the major obstacle in the treatment of cancer. The main factor behind is cancer stem cells (CSCs) which are more resistant to conventional chemotherapy, radiotherapy and are quite able to regenerate whole new tumor again if remain alive during treatment. Targeting CSCs along with actively dividing cancer cells may significantly contribute to the solution of the problem of resistance and relapse. Various approaches are implemented to eradicate CSCs which include CSC markers specific compounds, Drugs which disturb niche and various inhibitors/modulators of signaling pathways. Hedgehog (Hh), Wnt and Notch pathways are modulated/inhibited using various agents and shown beneficial results in multiple forms of cancer. Many inhibitors/modulators of these pathways have been entered in the clinical trials. MicroRNAs have also been developed as anti CSCs agents. In this review, we have covered current status of CSC targeting therapy based on CSC markers, CSC niche, Hedgehog, Wnt, Notch pathway along with MicroRNA based targeting strategies and possibility of implementation multi-targeted anti-CSC therapy for the better outcome of the results. © 2014 Bentham Science Publishers.

Singh R.P.,National Institute of Pharmaceutical Education and Research | Singh R.P.,Evalueserve SEZ Gurgaon Pvt. Ltd. | Ramarao P.,National Institute of Pharmaceutical Education and Research | Ramarao P.,Central University of Punjab
Toxicology Letters | Year: 2012

Silver nanoparticles (Ag NPs) are used in consumer products and wound dressings due to their antimicrobial properties. However, in addition to toxic effects on microbes, Ag NPs can also induce stress responses as well as cytotoxicity in mammalian cells. We observed that Ag NPs are efficiently internalized via scavenger receptor-mediated phagocytosis in murine macrophages. Confocal and electron microscopy analysis revealed that internalized Ag NPs localize in the cytoplasm. Ag NPs cause mitochondrial damage, induce apoptosis and cell death. These effects were abrogated in presence of Ag ion-reactive, thiol-containing compounds suggesting the central of Ag ions in Ag NP toxicity. Quantitative image analysis revealed that intracellular dissolution of Ag NPs occurs about 50 times faster than in water. In conclusion, we demonstrate for the first time that Ag NPs are internalized by scavenger receptors, trafficked to cytoplasm and induce toxicity by releasing Ag ions. © 2012 Elsevier Ireland Ltd.

Negi A.,Central University of Punjab | Ramarao P.,Central University of Punjab | Kumar R.,Central University of Punjab
Mini-Reviews in Medicinal Chemistry | Year: 2013

Advancements in understanding of the genetics, genomics, biochemistry and the pharmacology of cancer in human, have driven the current cancer chemotherapy to intently focus on development of target-based approaches rather than conventional approaches. From among the various targets identified, validated and inhibited at different hallmarks of cancer, protein tyrosine kinases (PTKs) have been exploited the most. Insulin receptors (IRs), insulin like growth factor receptors (IGF-1R) and their hybrid receptors belong to tyrosine kinase receptor (TKR) family, constitute a structural homology among them and generate a growth promoting IGF system on binding with either insulin, IGF-1 or IGF-2. The system induces the mitogenic effects through a torrent of cell signals produced as a result of cross talk with other growth promoting peptides and steroidal hormones, ultimately resulting in hijacking apoptosis and increasing cell proliferation and cell survival in cancer cells. Various strategies such as anti-IGF-1R antibodies, IGF-1 mimetic peptides, antisense strategies, IGF-1R specific peptide aptamers, targeted degradation of IGF-1R and expression of dominant negative IGF-1R mutants have been explored to inhibit the IGF-1R signaling. However, targeting IGF-1R with small molecules has gained considerable attention in last few years due to their ease of synthesis, ease of optimization of absorption, distribution, metabolism, excretion and toxicity (ADMET) parameters, oral route of administration, lesser side effects and cost effectiveness. The present review provides a broad overview and discusses the highlights on discoveries, SAR studies and binding interactions of small molecules with either IGF-1R active or allosteric sites reported till date. © 2013 Bentham Science Publishers.

Microwave accelerated and expedited cyclocondensation reactions of 2-(3-aryl-1H-pyrazol-5-yl)anilines (4) with diverse aryl aldehydes/triethyl orthoformate in water/MeCN (route D) and internal cyclocondensation and aromatization of 5-(2-aminophenyl)-4,5-dihydro-3-arylpyrazole-1-carbaldehyde (7) under MeOH (route E) for the synthesis of a series of pyrazolo[1,5-c] quinazolines and their derivatives (1a-1q) are reported. © 2014 Elsevier Ltd. All rights reserved.

Singh P.,Central University of Punjab | Alex J.M.,Central University of Punjab | Bast F.,Central University of Punjab
Medical Oncology | Year: 2014

Insulin and insulin-like growth factor (IGF) signaling system, commonly known for fine-tuning numerous biological processes, has lately made its mark as a much sought-after therapeutic targets for diabetes and cancer. These receptors make an attractive anticancer target owing to their overexpression in variety of cancer especially in prostate and breast cancer. Inhibitors of IGF signaling were subjected to clinical cancer trials with the main objective to confirm the effectiveness of these receptors as a therapeutic target. However, the results that these trials produced proved to be disappointing as the role played by the cross talk between IGF and insulin receptor (IR) signaling pathways at the receptor level or at downstream signaling level became more lucid. Therapeutic strategy for IGF-1R and IR inhibition mainly encompasses three main approaches namely receptor blockade with monoclonal antibodies, tyrosine kinase inhibition (ATP antagonist and non-ATP antagonist), and ligand neutralization via monoclonal antibodies targeted to ligand or recombinant IGF-binding proteins. Other drug-discovery approaches are employed to target IGF-1R, and IR includes antisense oligonucleotides and recombinant IGF-binding proteins. However, therapies with monoclonal antibodies and tyrosine kinase inhibition targeting the IGF-1R are not evidenced to be satisfactory as expected. Factors that are duly held responsible for the unsuccessfulness of these therapies include (a) the existence of the IR isoform A overexpressed on a variety of cancers, enhancing the mitogenic signals to the nucleus leading to the endorsement of cell growth, (b) IGF-1R and IR that form hybrid receptors sensitive to the stimulation of all three IGF axis ligands, and (c) IGF-1R and IR that also have the potential to form hybrid receptors with other tyrosine kinase to potentiate the cellular transformation, tumorigenesis, and tumor vascularization. This mini review is a concerted effort to explore and fathom the well-recognized roles of the IRA signaling system in human cancer phenotype and the main strategies that have been so far evaluated to target the IR and IGF-1R. © 2013 Springer Science+Business Media New York.

Chauhan M.,Central University of Punjab | Kumar R.,Central University of Punjab
Bioorganic and Medicinal Chemistry | Year: 2013

Pyrazolopyrimidines are the fused heterocyclic ring systems which structurally resemble purines which prompted biological investigations to assess their potential therapeutic significance. They are known to play a crucial role in numerous disease conditions. The advent of their first bioactivity as adenosine antagonistic property divulged their medicinal potential. Radioactivity test on mice cells, morphometric and serological tests on rat hepatocytes, antitumor testing against L1210 and P388 leukemias in mice threw light on their biophysical aspects of significance. Biochemical properties were explored via xanthine oxidase assay, antioxidant enzyme assays, Western blot analysis, mRNA expression of apoptopic genes, receptor binding assays, and tryptan blue exclusion cytotoxicity evaluation. The collective results of biochemical and biophysical properties foregrounded their medicinal significance in central nervous system, cardiovascular system, cancer, inflammation etc. The present manuscript to the best of our knowledge is the first compilation on synthesis and medicinal aspects including structure-activity relationships of pyrazolo[3,4-d]pyrimidines reported to date. © 2013 Elsevier Ltd. All rights reserved.

Munshi A.,Central University of Punjab | Sharma V.,Osmania University
Current Pharmaceutical Design | Year: 2015

Stroke is the fourth leading cause of mortality and neurological disability. It is caused by an intricate interplay of environmental and genetic factors. Genes not only influence susceptibility to stroke but have also been found to alter the response to pharmacological agents and may also influence the clinical outcome of the disease. Current treatment strategies for stroke include tissue plasminogen activator, antiplatelet agents and lipid lowering drugs. These act via diverse mechanisms of actions and are centered around the management of modifiable risk factors to prevent the recurrent stroke events. However, a significant number of patients experience poor clinical outcome due to recurrent stroke events and drug induced adverse reactions. Therefore, accurate risk management and targeted prevention strategies remain yet to be explored at the level of individual patients with stroke. Pharmacogenetic based research studies have identified the relation between genetic factors and inter-individual variability towards drug treatment. Several single nucleotide polymorphisms in genes encoding for metabolizers, transporters and target receptors have been reported to influence the pharmacokinetics and pharmacodynamics of drugs used in the treatment of stroke. Many candidate gene studies have investigated the role of genetic variants in association with altered drug response in stroke treatment. However, these results are limited to clinical trials and should be replicated in Genome Wide Association (GWAS) Studies. In addition to this long term follow up prospective studies would be helpful in predicting drug induced risk/benefit ratio. Pharmacogenetic studies will reveal the correlation between variation in drug responses on the basis of the individual’s genomic profile better known as Personalized or Individualized Medicines. This will also optimize risk assessment and will stratify the population requiring careful attention before prescribing a particular medicine to achieve maximum therapeutic benefit. Moreover, this will help in designing the novel therapeutic agents with a targeted approach. In this concern, the Genomics and Randomized Trials Network (GARNET) has been created, which is a Pharmacogenomics Consortium aimed to identify genetic variants affecting an individual's response to treatment with the help of advanced technology. This review will address the major issues of therapeutic failures concerned with existing drugs used in the treatment of stroke and the need for exploring new and targeted therapeutic strategies based on pharmacogenetics. © 2015 Bentham Science Publishers.

Alex J.M.,Central University of Punjab | Kumar R.,Central University of Punjab
Journal of Enzyme Inhibition and Medicinal Chemistry | Year: 2014

Pyrazoles, categorized as nitrogen-containing heterocycles, are well known for their interminable participation in the field of perpetual research and development of therapeutical active agents. As a consequence pyrazoles became an inevitable core of numerous drugs having diverse activities. The broad spectrum of activities portrayed by the pyrazoles instigated the researchers to modify the pyrazole ring as 4,5-dihydro-1H-pyrazoles commonly known as 2-pyrazolines. The present review is a concerted effort to retrace compounds covered from 2009-till date which owe diverse biological activities to the 2-pyrazoline scaffold and also condenses the retro-synthetic approaches employed for their synthesis. This endeavor culminated in revelation that inhibitory potential varied when the substituents in particular N-substituents of 2-pyrazolines were altered. © 2014 Informa UK Ltd.

Kumar S.,Central University of Punjab
Nonlinear Dynamics | Year: 2016

The Vakhnenko–Parkes (VP) equation with power law nonlinearity is analyzed for Painlevé test and for Lie symmetries. The Painlevé analysis of Vakhnenko–Parkes equation with power law nonlinearity is performed by the Kruskal approach to check the Painlevé property. The Lie group formalism is also applied to derive symmetries of this equation, the ordinary differential equations deduced are further studied, and some exact solutions are obtained. © 2016 Springer Science+Business Media Dordrecht

Loading Central University of Punjab collaborators
Loading Central University of Punjab collaborators